Glucona America, Inc. v. Ardisson (In Re Ardisson)

272 B.R. 346, 2001 Bankr. LEXIS 1834, 2001 WL 1715758
CourtUnited States Bankruptcy Court, N.D. Illinois
DecidedAugust 28, 2001
Docket19-05154
StatusPublished
Cited by36 cases

This text of 272 B.R. 346 (Glucona America, Inc. v. Ardisson (In Re Ardisson)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Glucona America, Inc. v. Ardisson (In Re Ardisson), 272 B.R. 346, 2001 Bankr. LEXIS 1834, 2001 WL 1715758 (Ill. 2001).

Opinion

MEMORANDUM OPINION

SUSAN PIERSON SONDERBY, Bankruptcy Judge.

Plaintiff Glucona America, Inc. (“Gluco-na”) moves for summary judgment on all counts of its complaint against Debtor Kenneth Ardisson (“Ardisson”). For the reasons set forth below, the motion is denied.

BACKGROUND

Ardisson, a chemical engineer, was employed by Glucona in 1996 to function initially as its managing director. Later, in 1997, Ardisson became president of Gluco-na and managing director of Glucona’s parent corporation, Glucona, B.V. (“B.V.”). In the course of the next few years, Ardisson spent much of his time in the Netherlands, where B.V. is incorporated, although his family remained in the United States. Ar-disson’s employment with Glucona ended in May or June 1999.

Ardisson and B.V. were parties to an October 2, 1997 written contract of employment (the “Employment Agreement”) that provided for a five-year term of employment. It is undisputed that the Employment Agreement contained provisions imposing an obligation of secrecy with respect to all particular details of Ardisson’s employment, and an obligation not to compete with Glucona and B.V. for a period of two years following his employment. Ar-disson also prepared and signed another agreement that required Glucona employees to return documents upon leaving Glu-cona’s employment. Like the Employment Agreement, this second agreement prohibited the disclosure of information concerning Glucona during or after an employee’s term of employment. Ardisson acknowledges that during the term of his employment, he was bound by the common law fiduciary duty to exercise the utmost good faith and loyalty toward Glucona.

*350 Glucona is a leading producer of gluco-nates, which are used in the production of diverse products in the food, pharmaceutical and industrial markets. Gluconates are obtained by fermentation of glucose derived from natural, environmentally compatible raw materials. Bacteria is apparently used in the fermentation process used to produce gluconates.

Ardisson admits that he was entrusted with confidential information concerning gluconate technology during his employment with Glucona. However, he states that certain aspects of Glucona’s technology are widely known. Ardisson’s expert also opines that Ardisson has not wrongfully disclosed any proprietary information or trade secrets owned by Glucona. According to Ardisson, Glucona did not take steps to protect the bacteria or the confidential information needed for its production of gluconates.

Looking to events that preceded his departure from Glucona, Ardisson states that he angered members of the Dutch management team by taking steps to terminate plans for a new factory in the Netherlands that was to be used in the production of Gluconal CAL (“CAL”), a calcium supplement produced and sold by Glucona. One of the factors motivating Ardisson’s decision to terminate the project was a severe downturn in the demand for CAL. To increase sales of CAL, Ardisson put a price-cutting strategy in place.

Ardisson maintains that after a major corporate reorganization was announced in April 1998, it became clear to him that there was no suitable position for him within the new intercorporate structure. Ardisson was angry that Glucona had not told him of the reorganization plans, which were already underway at the time he signed the five-year Employment Agreement.

Although the sequence of events is not totally clear from the evidentiary submissions in the record, it appears that Ardis-son’s strategy to boost CAL sales started to show positive results at a time when he would have been contemplating a departure from Glucona. As discussed below, the central issue in this litigation is whether Ardisson wrongfully competed with Glu-cona in the market for products like CAL.

Glucona contends that in the period after the reorganization was announced, Ar-disson expended Glucona’s assets as part of an undisclosed scheme to compete against the company. To that end, in fall 1998, Ardisson allegedly decided to shut down a major production initiative to expand a Janesville, Wisconsin plant where materials used in CAL could be produced. Later, in the winter and spring of 1998-99, Ardisson allegedly exceeded his authority by expending large amounts on a Buckeye, Arizona facility where CAL could be produced on a toll manufacture basis. The alleged plan was that if toll production for Glucona did not materialize, the Buckeye plant could be used by Ardis-son and certain associates for competition against Glucona. When he left Glucona, Ardisson allegedly took a computer hard drive containing confidential files and hundreds of company documents, among them customer lists, technical documents and research documents.

Glucona further maintains that after his termination, Ardisson prepared a prospectus and sought investors for the Buckeye plant, in which he would have a residuary one-fourth interest. While still an employee of Glucona and in pursuit of his plan, Ardisson also allegedly solicited other Glu-cona employees to join his venture. Two witnesses have testified that Ardisson asked that they take some of Glucona’s proprietary strain of bacteria. Both before and after leaving Glucona, Ardisson is *351 alleged to have worked on processes which would yield products in competition with Glucona. Glucona accuses Ardisson of having revealed trade secrets to a competitor who worked on developing a strain of bacteria for Ardisson’s new venture. Then, in an effort to gain their business, Ardisson allegedly provided information concerning the work on the bacteria to others of Glucona’s competitors. See Glu-cona’s Local Rule 402(M)(3) Statement, ¶¶ 27 38, 42-43.

Glucona’s technology expert has rendered the following opinion with respect to the alleged wrongs perpetrated:

... I assert that Glucona has proprietary confidential information and trade secrets in gluconate technology, which are of great value to the company. It is also my opinion that Kenneth Ardisson violated his duties to Glucona America, Inc. and professional ethics, and has tried to harm the company by disclosing the proprietary trade secrets and confidential information.

Datta Technical Expert Opinion Report at 2.

On December 23, 1999, Glucona filed a complaint against Ardisson in the United States District Court for the Northern District of Illinois (the “District Court”). That suit (the “District Court Action”) was based on the allegations summarized above. In the District Court Action, Glu-cona sought damages and injunctive relief for breach of an employee’s duty of loyalty, trade secret misappropriation and disclosure of confidential information. During the course of the litigation, the parties engaged in extensive written discovery and a substantial number of depositions were taken. The District Court Action was set for trial on October 2, 2000, but was dismissed without prejudice after Ardisson filed a voluntary petition for relief under Chapter 7 on September 19, 2000.

In Count I of the complaint in this adversary proceeding, Glucona seeks a finding that Ardisson is not discharged from liability for those wrongs alleged in the District Court Action. The cause of action is brought under § 523(a)(6) of the Bankruptcy Code, 11 U.S.C.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

BMO Harris Bank N.A. v. Brahos (In re Brahos)
589 B.R. 381 (N.D. Illinois, 2018)
Parkway Bank & Trust v. Casali (In re Casali)
517 B.R. 835 (N.D. Illinois, 2014)
Sargis v. Aguilar (In re Aguilar)
511 B.R. 507 (N.D. Illinois, 2014)
Santiago v. Hernandez (In Re Hernandez)
452 B.R. 709 (N.D. Illinois, 2011)
Reed v. Owens (In Re Owens)
449 B.R. 239 (E.D. Virginia, 2011)
Zamora v. Jacobs (In Re Jacobs)
448 B.R. 453 (N.D. Illinois, 2011)
Deady v. Hanson (In Re Hanson)
432 B.R. 758 (N.D. Illinois, 2010)
6050 Grant, LLC v. Hanson (In Re Hanson)
428 B.R. 475 (N.D. Illinois, 2010)
Jefferson v. Holland (In Re Holland)
428 B.R. 465 (N.D. Illinois, 2010)
Ocean Equity Group, Inc. v. Wooten (In Re Wooten)
423 B.R. 108 (E.D. Virginia, 2010)
Baermann v. Ryan (In Re Ryan)
408 B.R. 143 (N.D. Illinois, 2009)
Muscarello v. Blackburn (In Re Blackburn)
415 B.R. 668 (N.D. Illinois, 2009)
Neary v. Stamat (In Re Stamat)
395 B.R. 59 (N.D. Illinois, 2008)
Goldberg v. Ojeda (In Re Ojeda)
397 B.R. 67 (N.D. Illinois, 2008)

Cite This Page — Counsel Stack

Bluebook (online)
272 B.R. 346, 2001 Bankr. LEXIS 1834, 2001 WL 1715758, Counsel Stack Legal Research, https://law.counselstack.com/opinion/glucona-america-inc-v-ardisson-in-re-ardisson-ilnb-2001.